Kornimate/medical-research-clean huggingface dataset:
mobility in daily life and falls in parkinson's disease: potential for rehabilitation

Conditions: Parkinson Disease

Summary: the goal of this intervention is to explore the effectiveness of a turning intervention (turn-it) to improve quality of turning in participants with parkinson's disease (pd). an unique exercise program has been developed - turn-it - in which participants practice exercises that focus on physiological constraints that impair turning ability, such as axial rigidity, narrow base of support, bradykinesia, and inflexible set-shifting. the 60 participants with pd and a history of falls in the previous 12 months, will be randomized into a 6-week, 3x/week, one-on-one turn-it group or no-intervention control group. this pilot intervention study will determine the number of subjects needed for a future clinical trial and will determine the sensitivity to change with rehabilitation our daily-life turning quality measures (such as, mean and variability of number of steps to turn, turn amplitude, turn velocity). the investigators predict that the turn-it program will improve turning in daily life enough to justify a larger clinical trial.


Eligibility criteria:
inclusion criteria: 1. diagnosis of idiopathic pd from movement disorders neurologist with the united kingdom brain bank criteria of bradykinesia with 1 or more of the following - rest tremor, rigidity, and balance problems not from visual, vestibular, cerebellar or proprioceptive conditions 2. responsive to levodopa 3. hoehn \& yahr stages ii-iv 4. age range 55-85 years old 5. self-report of one or more falls in past 12 months 6. willing and able to attend exercise intervention sessions at ohsu campus, and also refrain from changes in anti-parkinson medications and exercise levels. exclusion criteria: 1. major musculoskeletal or neurological disorders, structural brain disease, epilepsy, acute illness or health history, other than pd 2. no medical condition that precludes exercise 3. moca ≤ 21 or inability to follow directions 4. excessive use of alcohol or recreational drugs 5. recent change in medication 6. inability to stand and walk for 2 minutes without an assistive device
cerab technique for aortoiliac occlusive disease

Conditions: Aortoiliac Occlusive Disease

Summary: to evaluate the safety and efficacy of the cerab technique as an alternative to surgical reconstruction for treatment of aorto-iliac occlusive disease.

according to the trans-atlantic inter-society consensus (tasc-ii), bypass grafting is the treatment of choice for extensive aortoiliac occlusive disease (aiod) due to the good long-term patency rates. however, surgical reconstruction is associated with peri-operative morbidity and mortality. kissing stent technique was introduced as an endovascular treatment alternative for bilateral aortoiliac occlusive disease in 1991. reported technical success rates varied with the use of bare metal stents in extensive aoid. the cobest trial showed that covered balloon expandable stents (cbes) have a superior primary patency rate and clinical improvement outcome at 24 months when compared with bare metal stents. cbes may immediately reduce the risk of procedural complications such as dissection, perforation, in-stent stenosis, and embolization. in 2013, cerab technique was introduced to improve endovascular treatment results by a more anatomical and physiological reconstruction, with a subsequent better clinical outcome. the cerab technique was developed to overcome the anatomical and physiological disadvantages of kissing stents such as flow disturbances leading to turbulence and stasis of blood, which may cause thrombus formation and intimal neohyperplasia. the early results of the cerab configuration are promising at 1-year follow up in a group of 130 patients with aoid and the 30-day major complication rate was 7.7%. cerab and chimney cerab (c-cerab) techniques may change the treatment algorithm of aiod and juxta-renal occlusive disease. it appears to be a safe and feasible alternative with promising results, being a valid alternative for surgery and/or kissing stents.

Eligibility criteria:
inclusion criteria: 1. age: 18 years and older patients. 2. patient presented with disabling claudication pain. 3. patient presented with rest pain. 4. patient presented with gangrene or atrophic changes. 5. provided written informed consent. 6. eligible anatomy for cerab technique. 7. tasc- (ii) classification as assigned in the study protocol (specified type b, c and d lesions). exclusion criteria: 1. age less than 18 years old. 2. patients with acute limb ischemia. 3. patients treated with open surgery and other endovascular techniques such as kissing stenting. 4. cerab configuration extending into aneurysmatic infrarenal aorta. 5. patient's life expectancy \<2 years as judged by the investigator. 6. patient has a psychiatric or other condition that may interfere with the study. 7. patient has a known allergy to any device component. 8. patients with a systemic infection who may be at increased risk of endovascular graft infection. 9. patient has a coagulopathy or uncontrolled bleeding disorder. 10. patient had a recent cerebrovascular accident (cva) or a myocardial infarction (mi) within the prior three months. 11. patient is pregnant (female patients of childbearing potential only).
purethal birch rush study

Conditions: Allergic Rhinitis; Allergic Rhinoconjunctivitis

Summary: this study investigates the safety of two up-dosing regimen. the safety of purethal birch will be evaluated in a rush regimen (maximum dose reached in 3 injections during 3 weeks) compared to the conventional regimen (maximum dose reached in 6 injections during 6 weeks). the primary endpoint of the sudy is the comparison of the proportions of the patients who have successfully reached the maintenance dose between the two treatment regimes. a similar previous study with purethal grasses has shown that the rush up-dosing scheme is as safe as the conventional up-dosing regime. therefore it is expected that up-dosing with purethal birch according to the rush regimen is as safe as using the conventional regimen.


Eligibility criteria:
inclusion criteria: * signed informed consent. * age ≥12 years. * allergic rhinitis/rhinoconjunctivitis related to birch pollen with or without concomitant mild to moderate persistent asthma * fev1\>70% for patients with a history of mild to moderate asthma, fev1\>70% or pef\>80% for patients without a history of asthma * a positive spt (mean wheal diameter ≥ 3mm compared to negative control and negative control should be negative) for birch pollen. * positive serum specific anti-birch ige-test (\>0.7 u/ml) within 1 year before randomization and/or a positive provocation test for birch pollen within 1 year before randomization. exclusion criteria: * immunotherapy (scit or slit) with birch pollen allergens within the past 5 years * any specific immunotherapy (scit or slit) during the study period * severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs * active malignancies or any malignant disease within the past 5 years * severe uncontrolled diseases that could increase the risk for patients participating in the study * acute/active inflammation or infection of the target organs at the start of the study * secondary changes of the target organ * diseases with a contraindication for the use of adrenaline * use of systemic steroids within 4 weeks before start of the study and during the study * treatment with systemic and local β-blockers * vaccination within one week before start of therapy or during the initiation phase * anti-ige therapy within the 6 months prior to inclusion and during the study * participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study * pregnancy, lactation or inadequate contraceptive measures for women of child-bearing age * alcohol, drug or medication abuse within the past year * any clinically significant abnormal laboratory parameter at screening * lack or expected lack of cooperation or compliance * severe psychiatric, psychological, or neurological disorders * patients who are employees of the sponsor, institution or 1st grade relatives or partners of the investigator

Keywords: immunotherapy birch pollen seasonal allergy up-dosing
prospective asian multicenter prostate cancer focal therapy study (proamfocal)

Conditions: Prostate Cancer

Summary: this is a multicenter observational study of patients undergoing focal therapy for prostate cancer in asia

patients undergoing focal cryotherapy, focal hifu, focal ire, focal laser ablation, or other partial gland ablation modalities for prostate cancer will be recruited.

Eligibility criteria:
inclusion criteria: * prostate adenocarcinoma * maximum gleason score 4+4 * maximum cancer volume 1.5 ml (up to 2 lesions) or 3 ml (single lesion) * maximum prostate specific antigen (psa) level 15 ng/dl * maximum clinical stage t2c * american society of anesthesiologist criteria 2 or less exclusion criteria: * extra-prostatic extension on multi parametric magnetic resonance imaging (mpmri); capsular contact is permitted

Keywords: focal therapy cryotherapy high intensity focused ultrasound irreversible electroporation focal laser ablation microwave ablation
influence of brain insulin sensitivity on peripheral insulin sensitivity

Conditions: Insulin Sensitivity

Summary: the researchers will investigate if brain insulin action influences peripheral insulin sensitivity in healthy humans.


Eligibility criteria:
inclusion criteria: * bmi \< 28 kg/m2 * normal hba1c * healthy volunteers exclusion criteria: * heparin induced thrombocytopenia (hit) * metal implants * cardial diseases * anemia * patients taking any kind of drugs

Keywords: whole body insulin sensitivity insulin action in the brain
covid-19 volumetric quantification on computer tomography using computer aided diagnostics

Conditions: COVID-19

Summary: the aim of the study is to asses the influence of computer aided diagnostic to the process of lung affection quantification on computer tomography in covid-19 confirmed patients.

the lung involvement of covid-19 patients has been showed to be correlated to clinical outcomes and became part of the clinical practice. even though various scores can be used, the affection estimation is usually done on computer tomography, using radiologists's estimation skills which is a highly subjective process. artificial intelligence is a known objective constant and therefore a potential radiologist complement. this trial aims at studying the effect of using a computer aided diagnostic software integrated in the normal clinical practice of radiologists from timisoara county emergency hospital. it uses the ai-probe analysis setup, which turns off the cad outputs for randomly chosen 50% the cases (control) and then compares the radiological reports for differences between the two arms.

Eligibility criteria:
inclusion criteria: * rt-pcr confirmed patients of covid-19 exclusion criteria: * 15 or lower

Keywords: cad ai artificial intelligence
blood gas analysis and buffering in cardiac arrest

Conditions: Cardiac Arrest

Summary: the debate over the administration of sodium bicarbonate in cardiac arrest has been going on for several decades, swinging like a pendulum from "first-line drug" to "not indicated" to the recent guidelines advocating "a small bolus under special conditions (metabolic acidosis, intoxication, long-term resuscitation)". a targeted, blood-gas controlled application under optimised ventilation conditions has not yet been evaluated prehospitally. our preliminary studies have shown that an arterial puncture/line as well as measurement of blood gases is feasible in preclinical conditions. this multicentre trial including 5 centres and 10 physician-staffed emergency systems is designed to compare, in a prospective randomised controlled study, the effect of a calculated dosage of sodium bicarbonate based on the patient´s base deficit and weight, on rosc (= return of spontaneous circulation) and on the secondary survival of cardiac arrest patients. the null hypothesis is that there is no or negative impact on survival.


Eligibility criteria:
inclusion criteria: * prehospitally started cardiopulmonary resuscitation (cpr) * advanced cardiac life support provided * age \>18 years * arterial ph \< 7,2 * arterial be \< -12 * arterial pco2 15-75 mmhg * arterial po2 \>35 mmhg exclusion criteria: * women of childbearing age * traumatic cardiac arrest
g-credit (gangnam-cohort for risk evaluation of diabetes and impaired glucose tolerance)

Conditions: Type 2 Diabetes; Impaired Glucose Intolerance

Summary: the prevalence of type 2 diabetes has consistently increased and type 2 diabetes can cause many types of vascular complications. diabetes develops due to glucose intolerance. early detection and intervention in the stage of glucose intolerance makes it afford to prevent overt diabetes and its complications. this study was designed to make a cohort of korean patients with glucose intolerance to construct a long term database about clinical characteristics of these patients.


Eligibility criteria:
inclusion criteria: 1. patients older than 20 years old who has visited gangnam severance hospital since january 2007. 2. patients with either diabetes or impaired glucose tolerance 3. patients with at least 6 months of follow-up period exclusion criteria: 1. patients with gestational diabetes, any active stage of cancer and severe disability

Keywords: diabetes dm complication
topical itraconazole in treating patients with basal cell cancer

Conditions: Skin Basal Cell Carcinoma

Summary: this phase 0 trial studies how well itraconazole gel works in treating patients with basal cell cancer. itraconazole gel may help to treat basal cell tumors in patients.

primary objectives: i. to determine if 12 weeks of topical itraconazole gel reduces basal cell carcinoma (bcc) biomarkers (gli1, the target gene of the hedgehog pathway). secondary objectives: i. to determine if topical itraconazole gel will decrease bcc size. outline: patients apply itraconazole topically twice daily (bid) and placebo topically bid for 12 weeks. after completion of study treatment, patients are followed up for up to 14 weeks.

Eligibility criteria:
inclusion criteria: * the subject must sign and date all informed consent statements; children will sign the assent form and their guardian will sign the consent form * the subject must be willing to apply the medications twice daily for 1 month * the subjects must have at least four bccs in non-cosmetically sensitive sites * for women of child-bearing potential, a negative urine pregnancy test * women of child-bearing potential are expected to use an effective method of birth control to prevent exposing a fetus to potentially dangerous agent with unknown risk * for male patients with female partners of childbearing potential, agreement to use adequate contraception while you are participating in the study and 1 month after applying your last dose exclusion criteria: * pregnancy or breast-feeding * history of congestive heart failure or other findings of ventricular dysfunction * history of current evidence of malabsorption or liver disease * current immunosuppression or taking immunosuppressive drugs * taking oral itraconazole * taking any medication known to affect hedgehog (hh) signaling pathway * the subject has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study; specifically these include the topical use to the study tumors of: glucocorticoids (ii) retinoids (e.g., etretinate, isotretinoin, tazarotene, tretinoin, adapalene) systemically or topically (iii) alpha-hydroxy acids (e.g., glycolic acid, lactic acid) to more than 5% of the skin during the six months prior to study entry (iv) 5-fluorouracil or imiquimod; also - treatment with systemic chemotherapy or agents known to be inhibitors of hh signaling within 60 days to starting study medication
perioperative evaluation of immuno-inflammatory parameters

Conditions: Combined Inflammatory and Immunologic Defect

Summary: this study consists of evaluations, using blood tests, various immune, inflammatory and coagulation parameters in the perioperative settings (different substudies), without changing anything to what is expected. this will allow us to clarify the possible impact of surgery and analgesia on perioperative activation of these pathways.

a significant number of published data can be concluded that surgery and anesthetic and analgesic techniques have an impact on immunity and inflammation. however, none of these studies have been performed with modern techniques, much more reliable evaluation of immune activity, such as the assessment of monocytic degranulation by flow cytometry. it is therefore important to document immune activity using these new techniques, our patients, perioperative. this will be analyzed, so observational, the potential impact of different therapeutic interventions the patient receives. this study consists of evaluations, using blood tests, various immune, inflammatory and coagulation parameters in the perioperative settings (different substudies), without changing anything to what is expected. this will allow us to clarify the possible impact of surgery and analgesia on perioperative activation of these pathways.

Eligibility criteria:
inclusion criteria: * surgical patients (and controls) exclusion criteria: * immune disorders
study of etoposide in treating patients with recurrent or metastatic breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether etoposide monotherapy is effective and safe in the treatment of recurrent or metastatic breast cancer in chinese female patients.

current recommended dosage of etoposide in treating breast cancer is 50 mg/m2 orally once a day for 21 days, repeated every 28 days. with retrospective data review, this study intends to adjust etoposide dose to 60 mg/m2 daily for 10 days, repeated every 21 days as a cycle, to investigate the effectiveness and safety of etoposide monotherapy in the treatment of recurrent or metastatic breast cancer in chinese female patients.

Eligibility criteria:
inclusion criteria: * age: 18-80 years old. * ecog status: 0-2. * histologic or cytologic diagnosis of locally advanced or metastatic breast cancer. * no more than three prior chemotherapies, adjuvant chemotherapy excluded. * received prior anthracycline, taxane therapy. * at least 4 weeks from previous chemotherapy. * measurable disease of \>=2 cm (\>=1 cm on spiral ct scan). * life expectancy of ≥ 3 months. * adequate organ functions: * hemoglobin ≥10.0 g/dl, absolute neutrophil count ≥1.5×10\^9/l, platelet count ≥100×10\^9/l, * creatinine clearance ≥60ml/min, * bilirubin ≤1.5 times upper limit of normal (uln); akp,ast and alt ≤2.5x uln(≤5x uln if due to liver metastases). * signed informed consent. * menopausal women or received surgical sterilization, women with children potential must not be pregnant or nursing with negative pregnancy test and willing to practice acceptable methods of birth control during the study and 3 months after the study. exclusion criteria: * pregnancy or lactation. * untreated or uncontrolled cns metastases, or with refractory psychiatric illness. * prior treatment with etoposide. * other primary malignancies within the past 5 years except for carcinoma in situ of the cervix or nonmelanoma skin cancer. * clinically significant heart diseases (e.g.congestive heart failure, symptomatic coronary disease, uncontrolled cardiac arrhythmia, myocardial infarction) within the past 12 months. * serious uncontrolled concurrent infection or metabolism disorder. * concurrent treatment for active peptic ulcer disease or with digestive disorders. * prior radiotherapy and major surgery within 3 weeks before screening. * less than 4 weeks since prior investigational agents. * metastases present in more than one-third whole liver. * unable or unwilling to comply with the study protocol. * unsuitable to participate in study, that in the opinion of the treating physician.

Keywords: recurrent metastatic breast cancer
development of urologic registry for personalized medicine in patients with urologic malignant diseases by analyzing microbiome

Conditions: Urological Malignancies; Prostate Cancer; Renal Cell Cancer; Bladder Cancer; Ureter Cancer

Summary: genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in korean population have been increased due to the aged population and the westernized lifestyles. with the advancement of technologies, studies have found that microbiome not only affects human physiological functions, such as metabolism, immunity, and haematopoiesis, but also plays a significant role in the development and progression of malignancies. however, the investigation of microbiome in urological malignances have been limited and few studies have been reported. therefore, the investigator tried to evaluate the usefulness of microbiome in detection and monitoring of urological malignancies in korean population. this study aims to use microbiome in tissue, plasma, stool and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. this study plan includes building big databases for microbiome of urological malignancies in korean population.


Eligibility criteria:
inclusion criteria: * patients diagnosed as urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) * patients who have undergone surgeries due to urological malignancies in severance hospital, sinchon from 2020.10 and 2030.10 * those who agree to give permission to use their human source information * those who agree with this study exclusion criteria: * those who do not agree with this study * vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making
bandage lenses in treating patients with ocular graft-versus-host disease

Conditions: Graft Versus Host Disease; Ophthalmologic Complications

Summary: this phase ii clinical trial studies how well bandage lenses work in treating patients with ocular graft versus host disease. bandage lenses may be helpful in relieving eye symptoms and damage caused by eye graft versus host disease.

primary objectives: i. to determine the symptom improvement after 2 weeks of therapy with bandage lenses. secondary objectives: i. to confirm short-term safety within 1 month after bandage lenses. ii. to determine improvement in ophthalmologic examinations after bandage lenses. iii. to explore the use of optical coherence tomography as an objective measure of corneal inflammation. outline: patients wear bandage lenses continuously for at least 3 months in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic graft versus host disease (gvhd) as defined by the national institutes of health (nih) criteria * ocular symptoms of nih eye score 2 or greater: * score 2: moderate dry eye symptoms partially affecting activities of daily living (adl) (requiring drops \> 3 x per day or punctal plugs), without vision impairment * score 3: severe dry eye symptoms significantly affecting adl (special eyewear to relieve pain) or unable to work because of ocular symptoms or loss of vision caused by keratoconjunctivitis * no new systemic immunosuppressive medications within 1 month prior to enrollment * subject has the ability to understand and willingness to sign a written informed consent document exclusion criteria: * absolute neutrophil count \< 1000/ul * known hypersensitivity or allergy to contact lenses * evidence of any active viral, bacterial, or fungal infection in the eyes that is progressive despite appropriate treatment * treatment with contact lenses within the previous 3 months for any indication * active psychiatric disorder, substance abuse or any other reason that would interfere with compliance with the study protocol

Keywords: chronic graft-versus-host disease eye